The estrogen receptor (ER) is an important target for endocrine treatment in breast cancer patients, and ER expression of the tumor is the main indication to start antihormonal treatment, as success rates heavily rely on ER status [1, 2]. This evidence concerns the gene ESR1 and breast carcinoma.